Danish healthcare leader Novo Nordisk (NVO -1.00%) has historically been a dominant player in the world of diabetes care and metabolic health. In addition to its GLP-1 franchise, the company boasts products that treat hemophilia, rare endocrine disorders, and various chronic cardiovascular conditions. Even as it navigates shifting executive leadership and pricing pressures in Western retail markets, the conglomerate represents a highly stable, cash-rich business backed by an extensive global manufacturing footprint.
Novo Nordisk originally kicked off the modern weight loss boom with its injectable semaglutide blockbusters, Ozempic and Wegovy. To counter pill-based competitors, Novo won landmark FDA approval for its Wegovy pill, creating the first once-daily oral GLP-1 specifically indicated for long-term weight management and cardiovascular risk reduction. Looking ahead, one of the most notable candidates in the company's near-term pipeline is CagriSema, a potent, fixed-dose injectable combination of semaglutide and cagrilintide.
Recent clinical trial results show that CagriSema delivers stronger weight loss and blood sugar control than Wegovy alone. By combining these two distinct mechanisms into one shot, Novo Nordisk could have a powerful next-generation weapon to defend its market share against Eli Lilly. The company has also officially rebranded its day-to-day operations to simply Novo.
At its highly anticipated Capital Markets Day, CEO Mike Doustdar revealed that the firm's sweeping organizational restructuring has resulted in 13,000 global job cuts to protect margins and aggressively streamline workflows. To protect its market share ahead of looming generic patent expiries for semaglutide, Novo's updated 2030 strategy details plans to launch more than five multi-blockbuster drugs.
Rather than relying solely on pure weight loss, management is diversifying its clinical pipeline across five distinct therapeutic pillars: obesity, type 2 diabetes, chronic liver diseases (MASH), blood disorders, and endocrine disorders. To accelerate its R&D across these sectors, the company has also established a broad drug-discovery alliance with AI pioneer Anthropic.
3. Viking Therapeutics
